Udayakumar, Suji
Thomson, Sasha
Razak, Albiruni R. Abdul
Chan, Kelvin K. W. http://orcid.org/0000-0002-2501-3057
Article History
Accepted: 16 September 2022
First Online: 5 October 2022
Declarations
:
: No external funding was used in the preparation of this article.
: Suji Udayakumar, Sasha Thomson, and Kelvin K. W. Chan declare that they have no conflicts of interest that might be relevant to the contents of this article. Albiruni R. Abdul Razak declares having received honoraria from Eli Lilly, Boehringer Ingelheim, Merck, Adaptimmune, GSK and having acted a consultant/advisor for Merck, Bristol Myers Squibb, Novartic, Karyophara, Boston Biochemical, Deciphera, Genentech, Roche, Pfizer, Medimmune, Eli-Lilly, Boehringer Ingelheim, Entremed/CASI Pharmaceutical, Amgen, Champions Oncology, Interion, Blueprint.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: Conceptualization: Kelvin K. W. Chan. Methodology: Kelvin K. W. Chan. Formal analysis and investigation: Suji Udayakumar, Sasha Thomson, Kelvin K. W. Chan. Writing—original draft preparation: Suji Udayakumar, Sasha Thomson. Writing—review and editing: Suji Udayakumar, Sasha Thomson, Albiruni R. Abdul Razak, Kelvin K. W. Chan. Supervision: Albiruni R. Abdul Razak, Kelvin K. W. Chan.